• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Illinois Talc Verdict Successor Liability Ruling Change The Bull Case For Kenvue (KVUE)?

    Simply Wall St·07/24/2026 15:36:26
    Listen to the news
    • In July 2026, the Illinois Appellate Court upheld a US$45,000,000 jury verdict for the family of Theresa Garcia, confirming that asbestos-contaminated Johnson & Johnson talc-based baby powder caused her mesothelioma and affirming all trial court rulings.
    • The court also confirmed that Kenvue and Johnson & Johnson Holdco (NA) Inc. can be held liable as successors to Johnson & Johnson’s former consumer products business, underscoring enduring legal exposure tied to legacy talc products.
    • We’ll now examine how this affirmation of successor liability in a major asbestos case affects Kenvue’s existing investment narrative and perceived risks.

    Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    Kenvue Investment Narrative Recap

    To own Kenvue, you need to believe in the resilience of its everyday consumer brands and its ability to simplify operations while integrating Kimberly Clark. The Illinois talc verdict underlines that legacy legal exposure remains a meaningful overhang, but it does not obviously alter the near term focus on the Kimberly Clark merger and upcoming earnings.

    The most relevant recent announcement here is the Illinois Appellate Court’s confirmation that Kenvue can be held liable as a successor to Johnson & Johnson’s former consumer products business. This ruling sits alongside ongoing merger execution, leadership changes and margin pressures, and may influence how investors weigh legal contingencies against the expected benefits of combining with Kimberly Clark.

    Yet beneath the merger headlines, investors should also be aware of the enduring successor liability risk tied to...

    Read the full narrative on Kenvue (it's free!)

    Kenvue's narrative projects $16.7 billion revenue and $2.3 billion earnings by 2029. This requires 2.9% yearly revenue growth and a $0.7 billion earnings increase from $1.6 billion today.

    Uncover how Kenvue's forecasts yield a $19.50 fair value, a 3% upside to its current price.

    Exploring Other Perspectives

    KVUE 1-Year Stock Price Chart
    KVUE 1-Year Stock Price Chart

    Three fair value estimates from the Simply Wall St Community span roughly US$19.50 to US$32.22 per share, showing how far apart individual views can be. You should weigh those opinions against Kenvue’s ongoing legal exposure from legacy talc products, which could influence how the business converts brand strength into future performance.

    Explore 3 other fair value estimates on Kenvue - why the stock might be worth as much as 70% more than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For Alternative Opportunities?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.